Inhibiting bone resorption
CA 2294595 C · Owner: Merck Sharp & Dohme Corp. · Inventors: Daifotis, Anastasia G.; Yates, A. John; Santora, Arthur C. Ii
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein. The compounds are bisphosphonates selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate etridronate, ibandronate, risedronate, piridronate pamidronate, zolendronate, optionally in combination with a histamine H2 antagonist.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 17, 1998 and granted August 21, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 17, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 17, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.